361 related articles for article (PubMed ID: 23456517)
1. Disaccharides in the treatment of hepatic encephalopathy.
Sharma P; Sharma BC
Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
3. Management of overt hepatic encephalopathy.
Sharma P; Sharma BC
J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S82-7. PubMed ID: 26041964
[TBL] [Abstract][Full Text] [Related]
4. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
Morgan MY
Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
[TBL] [Abstract][Full Text] [Related]
5. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
[TBL] [Abstract][Full Text] [Related]
6. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
7. Nonabsorbable disaccharides for hepatic encephalopathy.
Als-Nielsen B; Gluud LL; Gluud C
Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
[TBL] [Abstract][Full Text] [Related]
8. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
9. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
Als-Nielsen B; Gluud LL; Gluud C
BMJ; 2004 May; 328(7447):1046. PubMed ID: 15054035
[TBL] [Abstract][Full Text] [Related]
10. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
11. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy for the treatment and prevention of hepatic encephalopathy.
Mohammad RA; Regal RE; Alaniz C
Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
[TBL] [Abstract][Full Text] [Related]
13. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.
Lanthier PL; Morgan MY
Gut; 1985 Apr; 26(4):415-20. PubMed ID: 3979914
[TBL] [Abstract][Full Text] [Related]
14. Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review.
Zucker DM; Redulla R
Gastroenterol Nurs; 2019; 42(1):84-94. PubMed ID: 30688711
[TBL] [Abstract][Full Text] [Related]
15. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy.
Patil DH; Westaby D; Mahida YR; Palmer KR; Rees R; Clark ML; Dawson AM; Silk DB
Gut; 1987 Mar; 28(3):255-9. PubMed ID: 3570029
[TBL] [Abstract][Full Text] [Related]
16. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
Morgan MY; Hawley KE
Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
[TBL] [Abstract][Full Text] [Related]
17. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
18. Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other?
Capocaccia L; Riggio O
Hepatology; 1990 Aug; 12(2):368-70. PubMed ID: 2391075
[No Abstract] [Full Text] [Related]
19. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.
Heredia D; Caballería J; Arroyo V; Ravelli G; Rodés J
J Hepatol; 1987 Jun; 4(3):293-8. PubMed ID: 3598162
[TBL] [Abstract][Full Text] [Related]
20. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Rahimi RS; Brown KA; Flamm SL; Brown RS
Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
